Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Strong Bearish
-100.0
Shares of Japan's Sumitomo Pharma fell over 12% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
